Metformin Because extended-release metformin, compared with the immediate-release presentation, is associated with a lower incidence of gastrointestinal adverse effects, such as nausea, vomiting, dyspepsia, and diarrhea, opting for the extended-release presentation is the first step in preventing the adverse effects related to this medication.9,10 The mechanism of action through which metformin triggers gastrointestinal adverse effects is not known, but there is increasing evidence supporting the idea that the pathophysiologic mechanism is secondary to dysbiosis, given the reports that Intestinibacter spp
Amiri-Moghadam S, Nematy M, Eghtesadi S, Khalili M, Mojarrad M, Jazayeri S, Vosooghinia H, Khosravi A, Salehi M, Beheshti-Namdar A
The primary intended use of AOD-9604 centers on its ability to enhance fat metabolism through specific cellular mechanisms
-Auxilia no processo de recuperao aps o exerccio
What is the KLOW protocol